AtaiBeckley Inc

AtaiBeckley surges 28% after Trump’s FDA fast‑track order for psychedelic therapies—analyst upgrades and a new regulatory path could unlock big upside for investors.

AtaiBeckley explores $2B+ deals for its psychedelic nasal spray BPL‑003, seeking a sale, co‑commercial or royalty partnership to accelerate its depression therapy launch.

AtaiBeckley’s FDA‑backed Phase 3 launch of the intranasal rapid‑acting antidepressant BPL‑003 could transform treatment‑resistant depression, offering quick, durable relief.

AtaiBeckley Inc. shares fall to $3.75 as the Nasdaq‑listed mental‑health biotech, linked to Berlin’s ATAI Life Sciences, projects 2026 growth amid a P/E of –4.88, a 5.98 P/B and a $1.36 bn market cap.